ArticleThe Journal of organic chemistry2026
DNA-Protein Cross-Link Formation and Cellular Toxicity by Chimeric Bis-Electrophiles.
Article in The Journal of organic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
DNA-protein cross-links (DPCs) and DNA-DNA interstrand cross-links (ICLs) strongly block genetic expression. Chemical agents that preferentially produce one of these DNA damage types over the other are potentially useful cellular probes and pharmacological agents but are uncommon. A chimeric alkylating agent (MEBAC) selectively forms DPCs over ICLs by reacting with the ε-amine of lysine. Here we determine that the majority of DPCs formed by MEBAC in NCPs are between dG and lysines in the histone amino terminal tails. We also compare the reactivity of MEBAC and an isomer (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.